Two Sigma Advisers LP Has $7.09 Million Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Two Sigma Advisers LP trimmed its holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Free Report) by 19.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 535,952 shares of the company's stock after selling 133,400 shares during the period. Two Sigma Advisers LP owned 0.63% of Syndax Pharmaceuticals worth $7,085,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Octagon Capital Advisors LP bought a new stake in Syndax Pharmaceuticals in the fourth quarter worth $11,951,000. Renaissance Technologies LLC bought a new position in shares of Syndax Pharmaceuticals in the 4th quarter valued at approximately $9,002,000. Trexquant Investment LP lifted its holdings in Syndax Pharmaceuticals by 1,309.7% in the 4th quarter. Trexquant Investment LP now owns 471,292 shares of the company's stock worth $6,230,000 after purchasing an additional 437,859 shares during the last quarter. Altium Capital Management LLC acquired a new stake in Syndax Pharmaceuticals in the 4th quarter worth approximately $4,891,000. Finally, Cubist Systematic Strategies LLC bought a new stake in Syndax Pharmaceuticals during the fourth quarter worth approximately $4,734,000.

Syndax Pharmaceuticals Stock Up 1.9%

SNDX traded up $0.19 during trading on Wednesday, reaching $10.12. 1,820,032 shares of the company's stock were exchanged, compared to its average volume of 1,778,865. The company has a market capitalization of $870.80 million, a P/E ratio of -2.79 and a beta of 0.82. The business has a 50 day moving average price of $11.68 and a 200 day moving average price of $13.58. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $8.58 and a fifty-two week high of $25.07.

Syndax Pharmaceuticals (NASDAQ:SNDX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.98) EPS for the quarter, topping analysts' consensus estimates of ($1.04) by $0.06. The business had revenue of $20.04 million for the quarter, compared to the consensus estimate of $15.88 million. Syndax Pharmaceuticals's revenue was up 1900.0% on a year-over-year basis. During the same period in the previous year, the business posted ($0.85) earnings per share. As a group, research analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Wall Street Zen upgraded shares of Syndax Pharmaceuticals to a "sell" rating in a research note on Tuesday, May 6th. Guggenheim restated a "buy" rating and set a $32.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, May 6th. Scotiabank raised their price target on Syndax Pharmaceuticals from $16.00 to $17.00 and gave the company a "sector perform" rating in a research report on Tuesday, May 6th. JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $39.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 20th. Finally, HC Wainwright reiterated a "buy" rating and set a $51.00 price target on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $35.91.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).